Calamos Advisors LLC increased its stake in shares of Bristol-Myers Squibb Co. (NYSE:BMY) by 0.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 156,752 shares of the biopharmaceutical company’s stock after buying an additional 58 shares during the period. Calamos Advisors LLC’s holdings in Bristol-Myers Squibb were worth $11,529,000 at the end of the most recent quarter.
Other institutional investors also recently made changes to their positions in the company. Bank of Montreal Can bought a new position in shares of Bristol-Myers Squibb during the second quarter valued at about $154,732,000. Canada Pension Plan Investment Board boosted its position in shares of Bristol-Myers Squibb by 628.9% in the first quarter. Canada Pension Plan Investment Board now owns 1,323,821 shares of the biopharmaceutical company’s stock valued at $84,566,000 after buying an additional 1,142,200 shares during the last quarter. NN Investment Partners Holdings N.V. bought a new position in shares of Bristol-Myers Squibb during the first quarter valued at about $69,778,000. TIAA CREF Investment Management LLC boosted its position in shares of Bristol-Myers Squibb by 9.8% in the first quarter. TIAA CREF Investment Management LLC now owns 10,372,071 shares of the biopharmaceutical company’s stock valued at $662,568,000 after buying an additional 921,866 shares during the last quarter. Finally, BlackRock Institutional Trust Company N.A. boosted its position in shares of Bristol-Myers Squibb by 1.9% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 44,742,184 shares of the biopharmaceutical company’s stock valued at $2,858,131,000 after buying an additional 844,233 shares during the last quarter. Institutional investors and hedge funds own 72.87% of the company’s stock.
Bristol-Myers Squibb Co. (NYSE:BMY) traded up 1.44% during mid-day trading on Tuesday, reaching $50.05. The company’s stock had a trading volume of 8,773,340 shares. The firm has a market capitalization of $83.63 billion, a P/E ratio of 29.27 and a beta of 0.75. Bristol-Myers Squibb Co. has a 52 week low of $49.10 and a 52 week high of $77.12. The firm’s 50 day moving average price is $54.57 and its 200 day moving average price is $66.13.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.66 by $0.03. The business had revenue of $4.90 billion for the quarter, compared to the consensus estimate of $4.60 billion. Bristol-Myers Squibb had a return on equity of 24.92% and a net margin of 16.63%. The business’s revenue was up 17.2% on a year-over-year basis. During the same quarter last year, the business posted $0.53 EPS. On average, analysts anticipate that Bristol-Myers Squibb Co. will post $2.63 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, November 1st. Investors of record on Friday, October 7th will be issued a $0.38 dividend. This represents a $1.52 annualized dividend and a dividend yield of 3.04%. The ex-dividend date is Wednesday, October 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 87.36%.
Several equities research analysts recently weighed in on BMY shares. Credit Suisse Group AG cut Bristol-Myers Squibb from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $86.00 to $63.00 in a research note on Sunday, August 7th. Leerink Swann restated an “outperform” rating and set a $69.00 target price on shares of Bristol-Myers Squibb in a research note on Sunday, October 9th. Morgan Stanley restated a “hold” rating on shares of Bristol-Myers Squibb in a research note on Thursday, August 25th. Jefferies Group restated a “hold” rating and set a $57.00 target price (down previously from $69.00) on shares of Bristol-Myers Squibb in a research note on Monday, September 12th. Finally, Goldman Sachs Group Inc. restated a “buy” rating and set a $75.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, September 27th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $69.06.
In related news, Director Lamberto Andreotti sold 21,600 shares of the firm’s stock in a transaction that occurred on Thursday, September 8th. The stock was sold at an average price of $56.87, for a total value of $1,228,392.00. Following the sale, the director now owns 334,499 shares of the company’s stock, valued at approximately $19,022,958.13. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.24% of the stock is owned by corporate insiders.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co. (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co. and related companies with MarketBeat.com's FREE daily email newsletter.